2025 Global Autologous Cell Therapy Market Revenue Opportunities Report
Description
The 2025 Global Autologous Cell Therapy Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Autologous Cell Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the autologous cell therapy market on a global scale include Novartis, Bristol Myers Squibb, Gilead Sciences (Kite Pharma), and Autolus Therapeutics. Novartis is a prominent leader with its CAR-T therapy candidate Kymriah, expanding into new indications like follicular lymphoma and committing significant investments in manufacturing capacity. Bristol Myers Squibb distinguishes itself with a broad pipeline, including autoimmune disease programs, and recently acquired 2seventy bio to bolster its cell therapy capabilities. Gilead Sciences (through Kite Pharma) advances multiple CAR-T therapies like Yescarta, focusing on hematologic malignancies with noteworthy FDA approvals and process enhancements that reduce manufacturing time. Autolus Therapeutics collaborates with BioNTech, emphasizing novel CAR-T programs targeting solid tumors.
Other notable companies include Vericel Corporation and Pharmicell Co., Ltd., which hold significant market shares with diverse pipelines in regenerative and autologous therapies. These leaders drive the autologous cell therapy market growth through strategic partnerships, clinical development, and technology innovations focused on personalized regenerative medicine across oncology, autoimmune, and degenerative diseases. The North American region, particularly the U.S., dominates through substantial healthcare infrastructure support, favorable regulatory pathways (e.g., FDA RMAT designation), and strong industry investments.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Autologous Cell Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the autologous cell therapy market on a global scale include Novartis, Bristol Myers Squibb, Gilead Sciences (Kite Pharma), and Autolus Therapeutics. Novartis is a prominent leader with its CAR-T therapy candidate Kymriah, expanding into new indications like follicular lymphoma and committing significant investments in manufacturing capacity. Bristol Myers Squibb distinguishes itself with a broad pipeline, including autoimmune disease programs, and recently acquired 2seventy bio to bolster its cell therapy capabilities. Gilead Sciences (through Kite Pharma) advances multiple CAR-T therapies like Yescarta, focusing on hematologic malignancies with noteworthy FDA approvals and process enhancements that reduce manufacturing time. Autolus Therapeutics collaborates with BioNTech, emphasizing novel CAR-T programs targeting solid tumors.
Other notable companies include Vericel Corporation and Pharmicell Co., Ltd., which hold significant market shares with diverse pipelines in regenerative and autologous therapies. These leaders drive the autologous cell therapy market growth through strategic partnerships, clinical development, and technology innovations focused on personalized regenerative medicine across oncology, autoimmune, and degenerative diseases. The North American region, particularly the U.S., dominates through substantial healthcare infrastructure support, favorable regulatory pathways (e.g., FDA RMAT designation), and strong industry investments.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
